首页 | 本学科首页   官方微博 | 高级检索  
检索        

CYP2C19多态性对奥美拉唑药代动力学的影响
引用本文:罗薇,王鹤尧,刘丽宏,李鹏飞,祝锦,宫丽丽,于晓佳,邱葵,周虹,张征.CYP2C19多态性对奥美拉唑药代动力学的影响[J].临床药物治疗杂志,2013,0(2):22-26.
作者姓名:罗薇  王鹤尧  刘丽宏  李鹏飞  祝锦  宫丽丽  于晓佳  邱葵  周虹  张征
作者单位:罗薇 (首都医科大学附属北京朝阳医院药事部 北京 100020);王鹤尧** (首都医科大学附属北京朝阳医院药事部 北京 100020);刘丽宏** (首都医科大学附属北京朝阳医院药事部 北京 100020);李鹏飞 (首都医科大学附属北京朝阳医院药事部 北京 100020); 祝锦 (首都医科大学附属北京朝阳医院药事部 北京 100020);宫丽丽 (首都医科大学附属北京朝阳医院药事部 北京 100020); 于晓佳 (首都医科大学附属北京朝阳医院药事部 北京 100020); 邱葵 (首都医科大学附属北京朝阳医院药事部 北京 100020); 周虹 (首都医科大学附属北京朝阳医院药事部 北京 100020); 张征 (首都医科大学附属北京朝阳医院药事部 北京 100020);
基金项目:药物使用安全与输血安全相关技术与标准研究(200902008)
摘    要:目的:研究中国健康受试者细胞色素P4502C19(CYP2C19)多态性对奥美拉唑体内药代动力学的影响。方法:筛选12名健康男性和12名健康女性受试者,采用随机分组、双交叉的试验方案,每组分别服用一种奥美拉唑7d,洗脱期7d,第2周期交换用药。用LC-MS/MS方法测定每周期第1天和第7天多个时间点血药浓度,计算两种奥美拉唑的药代动力学参数。检测受试者基因位点CYP2C19*2(681G>A)和CYP2C19*3(636G>A),按照基因型分成快代谢型、中等代谢型和慢代谢型。结果:慢代谢型、中等代谢型和快代谢型在药代动力学参数t1/2、MRT0-t、CL、Vd、AUC0-t、AUC0-∞中存在显著性差异(P<0.05),连续给药后基因多态性对药物代谢的影响相对减小。结论:CYP2C19多态性与奥美拉唑的代谢密切相关,临床上应关注基因多态性对奥美拉唑代谢的影响。

关 键 词:奥美拉唑  药代动力学  细胞色素P4502C19  基因多态性

Effect of CYP2C19 Polymorphisms on Pharmacokinetics of Omeprazole
Luo Wei Wang He-yao,Liu Li-hong,Li Peng-fei,Zhu Jin,Gong Li-li,Yu Xiao-jia,Qiu Kui,Zhou Hong,Zhang Zheng.Effect of CYP2C19 Polymorphisms on Pharmacokinetics of Omeprazole[J].Clinical Medication JOurnal,2013,0(2):22-26.
Authors:Luo Wei Wang He-yao  Liu Li-hong  Li Peng-fei  Zhu Jin  Gong Li-li  Yu Xiao-jia  Qiu Kui  Zhou Hong  Zhang Zheng
Institution:. Pharmacy Department of Beijing Chao-Yang Hospital affikiated to Capital Medical University, Beijing 100020, China
Abstract:Objective: To study the effect of CYP2C19 polymorphisms on the pharmacokinetics of omeprazole in chinese healthy subjects. Methods: We performed a randomized, two-period ,crossover study involving 24 healthy subjects (12 men and12 women). All healthy subjects were randomly assigned to omeprazole magnesium enteric-coated tablets or omeprazole capsules, After 7 days of washout period, omeprazole magnesium enteric-coated tablets group and omeprazole capsules group exchanged. The plasma concentrations of omeprazole were measured by LC-MS/MS on day1,7 of each period and the pharmacokinetic parameters were analyzed. Meanwhile, based on the analysis of the subjects' CYP2C19*2(681G〉A)and CYP2C19*3(636G〉A), they were classified into extensive metabolizers, intermediate metabolizers and poor metabolizers. Results: t1/2, MRTo-t, CL, Vo, AUCo-t and AUC0-∞ among3 metabolizer groups were significant differences (P〈0.05). After repetitive administration, the effect of genetic polymorphism on drug metabolisms decreased. Conclusions: There was a close relationship between CYP2C19 genetic polymorphisms and the metabolism of omeprazole, and this should be concerned in clinical treatment.
Keywords:omeprazole  pharrnacokinetics  CYP2C19  genetic polymorphism  
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号